Skip to main content
SpringerLink
Log in

Anticorps anti-VEGF: un emploi universel

  • Chapter
Les thérapies ciblées

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 374 Accesses

Abstrait

Les très nombreux travaux menés depuis les années soixante sur le rôle de ľangiogenèse dans les cancers ont permis ďaboutir à des traitements ciblant ce processus physiopathologique (1, 2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–6

    PubMed  CAS  Google Scholar 

  2. Giantonio BJ, Levy DE, O’dwyer PJ, et al. (2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17: 1399–1403

    Article  PubMed  CAS  Google Scholar 

  3. Folkman J (1995) Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757–63

    Article  PubMed  CAS  Google Scholar 

  4. Gross J, Azizkhan RG, Biswas C, et al. (1981) Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. Proc Natl Acad Sci USA 78: 1176–80

    Article  PubMed  CAS  Google Scholar 

  5. Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1: 149–53

    Article  PubMed  CAS  Google Scholar 

  6. Inoue M, Hager JH, Ferrara N, et al. (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1: 193–202

    Article  PubMed  CAS  Google Scholar 

  7. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368–80

    Article  PubMed  CAS  Google Scholar 

  8. Shinkaruk S, Bayle M, Lain G, Deleris G (2003) Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 3: 95–117

    Article  PubMed  CAS  Google Scholar 

  9. Martiny-Baron G, Marme D (1995) VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Curr Opin Biotechnol 6: 675–80

    Article  PubMed  CAS  Google Scholar 

  10. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510–4

    Article  PubMed  CAS  Google Scholar 

  11. Fujita M, Hayashi I, Yamashina S, et al. (2005) Angiotensin type la receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26(2): 271–9

    Article  PubMed  CAS  Google Scholar 

  12. Luo Y, Zhou H, Krueger J, et al. (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116: 2132–41

    Article  PubMed  CAS  Google Scholar 

  13. Weidner N, Folkman J, Pozza F, et al. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875–87

    Article  PubMed  CAS  Google Scholar 

  14. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64: 2941–55

    Article  PubMed  CAS  Google Scholar 

  15. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–42

    Article  PubMed  CAS  Google Scholar 

  16. Reddy GK (2005) The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. Clin Colorectal Cancer 4: 300–1

    PubMed  Google Scholar 

  17. Yang JC, Haworth L, Sherry RM, et al. (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–34

    Article  PubMed  CAS  Google Scholar 

  18. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JJO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007 Dec 22; 370(9605): 2103–11

    Article  PubMed  Google Scholar 

  19. Miller KD, Chap LI, Holmes FA, et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–9

    Article  PubMed  CAS  Google Scholar 

  20. Miller K, Wang M, Gralow J, Dickler M, Cobleig M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med:27; 357(26): 2666–76

    Article  PubMed  CAS  Google Scholar 

  21. Johnson DH, Fehrenbacher L, Novotny WF, et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184–91

    Article  PubMed  CAS  Google Scholar 

  22. Sandler AB, Gray R, Brahmer J, et al. (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trialFE4599 [abstract LBA4]. J Clin Oncol 23: 2S

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de médecine interne, Centre Henri Becquerel, Rue ďAmiens, 76038, Rouen Cedex

    E. Blot

  2. Service ďoncologie médicale, CHU Avicenne, 125, route de Stalingrad, 93009, Bobigny

    G. des Guetz

Authors
  1. E. Blot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. des Guetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France

About this chapter

Cite this chapter

Blot, E., des Guetz, G. (2008). Anticorps anti-VEGF: un emploi universel. In: Les thérapies ciblées. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36008-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-36008-4_4

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-36007-7

  • Online ISBN: 978-2-287-36008-4

Publish with us

Policies and ethics

Search

Navigation